Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ann Emerg Med ; 73(1): 79-87, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-29880440

RESUMEN

STUDY OBJECTIVE: Cancer immunotherapy is evolving rapidly and is transforming cancer care. During the last decade, immune checkpoint therapies have been developed to enhance the immune response; however, specific adverse effects related to autoimmunity are increasingly apparent. This study aims to fill the knowledge gap related to the spectrum of immune-related adverse effects among cancer patients visiting emergency departments (EDs). METHODS: We performed a retrospective review of patients treated with immune checkpoint therapy who visited the ED of a comprehensive cancer center between March 1, 2011, and February 29, 2016. Immune-related adverse effects from the ED visits were identified and profiled. We analyzed the association of each immune-related adverse effect with overall survival from the ED visit to death. RESULTS: We identified 1,026 visits for 628 unique patients; of these, 257 visits (25.0%) were related to one or more immune-related adverse effects. Diarrhea was the most common one leading to an ED visit. The proportions of ED visits associated with diarrhea, hypophysitis, thyroiditis, pancreatitis, or hepatitis varied significantly by immune checkpoint therapy agent. Colitis was significantly associated with better prognosis, whereas pneumonitis was significantly associated with worse survival. CONCLUSION: Cancer patients treated with ipilimumab, nivolumab, or pembrolizumab may have a spectrum of immune-related adverse effects that require emergency care. Future studies will need to update this profile as further novel immunotherapeutic agents are added.


Asunto(s)
Antineoplásicos Inmunológicos/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/clasificación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Neoplasias/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Servicios Médicos de Urgencia , Servicio de Urgencia en Hospital , Femenino , Humanos , Inmunoterapia/efectos adversos , Ipilimumab/efectos adversos , Masculino , Persona de Mediana Edad , Neoplasias/inmunología , Nivolumab/efectos adversos , Prevalencia , Pronóstico , Estudios Retrospectivos , Adulto Joven
2.
Ochsner J ; 13(4): 544-6, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24358004

RESUMEN

BACKGROUND: Practice standards recommend that the induction of epidural analgesia for labor begin with a test dose of local anesthetic with epinephrine. During the test dose period and following anesthetic administration, the anesthesiologist measures the parturient's pulse with continuous pulse oximetry to help detect the intravascular placement of the epidural catheter as evidenced by the abrupt onset of tachycardia. CASE REPORT: We report the onset of tachycardia in a healthy parturient following induction of continuous epidural analgesia. The tachycardia was ultimately diagnosed as lone atrial fibrillation-a finding not previously reported in the literature. CONCLUSION: We initially thought the diagnosis portended undetected cardiac disease, but further assessment found no cardiac abnormalities.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA